

UBS ETF (LU) Solactive China Technology UCITS ETF (USD) A-acc

Fund Fact Sheet

UBS Exchange Traded Funds > UBS ETF SICAV

Fund description

- The fund generally invests in the Solactive China Technology Index USD. The relative weightings of the companies correspond to their weightings in the index.
- The investment objective is to replicate the price and return performance of the Solactive China Technology Index USD net of fees. The stock exchange price may differ from the net asset value.
- The fund is passively managed.
- The product described herein aligns to Article 6 of Regulation (EU) 2019/2088.

Name of fund	UBS (Lux) Fund Solutions – Solactive China Technology UCITS ETF
Share class	UBS (Lux) Fund Solutions – Solactive China Technology UCITS ETF (USD) A-acc
ISIN	LU2265794276
UCITS V	yes
Launch date	05.03.2021
Currency of fund / share class	USD/USD
Management fee p.a.	0.47%
Total expense ratio (TER) p.a. ¹	0.47%
Name of the Management Company:	UBS Fund Management (Luxembourg) S.A., Luxembourg
Accounting year end	31 December
Distribution	Reinvestment
Replication methodology	Physical (Full replicated)
Portfolio management representatives	UBS Asset Management (UK) Ltd., London
Fund domicile	Luxembourg

¹ as at 30.06.2022


Fund statistics

Net asset value (USD, 30.12.2022)	5.96
Last 12 months (USD) – high	8.88
– low	4.30
Total fund assets (USD m)	29.89
Share class assets (USD m)	23.21

	2 years	3 years	5 years
Volatility ¹			
– Fund	n.a.	n.a.	n.a.
– Benchmark	n.a.	n.a.	n.a.
Tracking error (ex post)	n.a.	n.a.	n.a.

¹ Annualised standard deviation

Performance (basis USD, net of fees)¹



- Fund performance net of fees (left-hand scale)
- Fund performance per year in % net of fees (right-hand scale)
- Index performance (left-hand scale)

Past performance is not a reliable indicator of future results.

Percentage growth (%)	1 year	2 years	3 years	Ø p.a. 2 years	Ø p.a. 3 years
Fund (USD)	-31.86	n.a.	n.a.	n.a.	n.a.
Ref. Index ²	-31.67	-53.07	-15.90	-31.49	-5.61

Percentage growth (%)	Q4 2021 to Q4 2022	Q4 2020 to Q4 2021	Q4 2019 to Q4 2020	Q4 2018 to Q4 2019	Q4 2017 to Q4 2018
Fund (USD)	-31.86	n.a.	n.a.	n.a.	n.a.
Ref. Index ²	-31.67	-31.32	79.19	n.a.	n.a.

- ¹ These figures refer to the past. If the currency of a financial product, financial service or its costs is different from your reference currency, the return and/or costs can increase or decrease as a result of currency fluctuations. Source for all data and chart (if not indicated otherwise): UBS Asset Management.
- ² Reference Index in currency of share class (without costs)

Index description

The Solactive China Technology Index NTR intends to track the performance of the 100 largest technology-driven Chinese companies which derive the majority of their revenues from various innovative business activities, including cloud computing, medical technologies, future mobility, or digital entertainment. The Index is a free float adjusted market capitalization weighted index with a security weight cap of 10%.

Index name	Solactive China Technology Total Return Net
Index type	Total Return Net
Number of index constituents	97
Bloomberg	.SCNTECUN
Reuters	.SCNTECUN

For more information

Phone: 0800-587 2111
Internet: www.ubs.com
Contact your client advisor

Registrations for public distribution

AT, CH, DE, DK, ES, FI, FR, GB, IT, LI, LU, NL, NO, PT, SE

UBS ETF (LU) Solactive China Technology UCITS ETF (USD) A-acc

Sector exposure (%)

	Index
Consumer Discretionary	37.0
Communication Services	29.1
Health Care	14.5
Information Technology	13.4
Industrials	2.9
Real estate	1.5
Financial Services	1.2
Others	0.4

10 largest equity positions (%)

	Index
TENCENT HOLDINGS LTD	11.36
ALIBABA GROUP HOLDING-SP ADR	9.85
MEITUAN	9.48
PINDUODUO INC	7.36
BAIDU INC - SPON ADR	5.60

Benefits

Clients benefit from the flexibility of an exchange-traded investment.
 Provides access to the China technology market with a single transaction.
 Optimised risk/return profile thanks to a broad diversification across a range of equity factors and sectors.
 The fund offers a high degree of transparency and cost efficiency.
 UCITS compliant fund.

Currency exposure (%)

	Index
HKD	48.95
USD	42.17
CNH	8.88

	Index
WUXI BIOLOGICS CAYMAN INC	4.91
NETEASE INC-ADR	4.84
BYD CO LTD	3.90
XIAOMI CORP	3.69
NIO INC - ADR	2.58

Risks

This UBS Exchange Traded Fund invests in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. Sustainability risks are not considered as part of the Index selection process. Therefore, sustainability risks are not systematically integrated. As a result, the net asset value of the funds assets is directly dependent on the performance of the underlying index. Losses that could be avoided via active management will not be offset.

Listing and trading information

Exchange	Trading currency	Trading hours (local time)	Bloomberg Ticker	Reuters RIC	iNAV Bloomberg
Borsa Italiana	EUR	09:00am - 05:30pm CET	CIT IM	CIT.MI	CITEUIV
Deutsche Börse (XETRA)	EUR	09:00am - 05:30pm CET	UIC2 GY	UIC2.DE	CITEUIV
London Stock Exchange	GBX	09:00am - 05:30pm CET	CHTE LN	CHTE.L	CITEUIV
SIX Swiss Exchange	USD	09:00am - 05:30pm CET	CQQQ SW	CQQQ.S	CQQQUSIV

Important information

Past performance is not a guide to future performance. The value of investments and the income from them may go down as well as up and are not guaranteed. Investors may not get back the amount originally invested. Changes in rates of exchange may cause the value of this investment to fluctuate. The information contained in this document should not be considered a recommendation to purchase or sell any particular security and the opinions expressed are those of UBS Asset Management and are subject to change without notice. UBS funds make use of the Temporary Permissions Regime allowing EEA-domiciled funds to be distributed in the UK for a limited period until full authorisation is obtained. For reporting fund status, please visit the HMRC's website. The protections offered by the UK's regulatory system, and compensation under the Financial Services Compensation Scheme, will not be available.

UBS ETF (LU) Solactive China Technology UCITS ETF (USD) A-acc

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing and to get complete information of the risks. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. For a definition of financial terms refer to the glossary available at www.ubs.com/am-glossary.

For marketing and information purposes by UBS. UBS funds under Luxembourg law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). UBS Asset Management (UK) Ltd is authorized & regulated by the Financial Conduct Authority. Prospectuses, Key investor information (KIID), the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available free of charge from UBS Asset Management (UK) Ltd, 5 Broadgate, London, EC2M 2QS. The fund documentation is available free of charge in English and, where relevant, in one of the local language(s) where the fund is registered and online at www.ubs.com/etf. The product described herein aligns to Article 6 Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. Information on sustainability-related aspects pursuant to that regulation can be found on www.ubs.com/funds. The benchmark is the intellectual property of the respective index provider. The fund or the share class is neither sponsored nor endorsed by the index provider. The fund prospectus or supplemental prospectus contains the full disclaimer. Before investing in a product please read the latest prospectus and key investor information document carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the fund as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Members of the UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. If whole or part of the total costs to be paid is different from your reference currency, the costs may increase or decrease as a result of currency and exchange rate fluctuations. Commissions and costs have a negative impact on the investment and on the expected returns. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency and exchange rate fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Future performance is subject to taxation which depends on the personal situation of each investor and which may change in the future. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS Asset Management Switzerland AG or a local affiliated company. Source for all data and charts (if not indicated otherwise): UBS Asset Management. A summary of investor rights in English can be found online at www.ubs.com/funds. More explanations of financial terms can be found at www.ubs.com/am-glossary.

© UBS 2023. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

1897042|1897041